We determined the effect of 6-month rosuvastatin treatment on blood lipids, oxidative parameters, apolipoproteins, high-sensitivity C-reactive protein, lipoprotein(a), homocysteine, and glycated hemoglobin (HbA1c) in patients with metabolic syndrome (MetS). Healthy individuals (men aged >40 years and postmenopausal women) with a body mass index ≥30 (n = 100) who fulfilled the National Cholesterol Education Program Adult Treatment Panel III diagnostic criteria for MetS were included. Total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels decreased (P < .0001). The change in LDL 1 to 3 subgroups was significant (P = .0007, P < .0001, and P = .006, respectively). Changes in LDL 4 to 7 subgroups were not significant. There was a beneficial effect on oxidized LDL, fibrinogen, homocysteine, and HbA1c. Rosuvastatin significantly increased high-density lipoprotein levels (P = .0003). The oxidant/antioxidant status and subclinical inflammatory state were also beneficially changed. Rosuvastatin had a significant beneficial effect on atherogenic dyslipidemia as well as on oxidative stress and inflammatory biomarkers in patients with MetS.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
2.
EinhornDReavenGMCobinRH. American college of endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237–252.
3.
GrundySMCleemanJIDanielsSR. American heart association; national heart, lung, and blood institute. diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112(17):2735–2752.
4.
RodríguezADelgado-CohenHReviriegoJSerrano-RíosM. Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, third report national cholesterol education program, and international diabetes federation definitions. Diabetes Metab Syndr Obes. 2010;4:1–4.
5.
RizzoMBerneisK. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006;99(1):1–14.
6.
BerneisKKKraussRM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363–1379.
7.
GaziITsimihodimosVFilippatosTBairaktariETselepisADElisafM. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the national cholesterol education program criteria. Metabolism. 2006;55(7):885–891.
8.
JuliusUDittrichMPietzschJ. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int J Clin Pract. 2007;61(11):1798–1804.
9.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
10.
MuddJOBorlaugBAJohnstonPV. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50(18):1735–1741.
11.
El HarchaouiKvan der SteegWAStroesES. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-norfolk prospective population study. J Am Coll Cardiol. 2007;49(5):547–553.
12.
HammondMGFisherWR. The characterization of a discrete series of low density lipoproteins in the disease, hyper-pre-beta-lipoproteinemia. implications relating to the structure of plasma lipoproteins. J Biol Chem. 1971;246(17):5454–5465.
13.
JungnerISnidermanADFurbergCAastveitAHHolmeIWalldiusG. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?Am J Cardiol. 2006;97(7):943–946.
14.
StampferMJKraussRMMaJ. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276(11):882–888.
15.
El HarchaouiKArsenaultBJFranssenR. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150(2):84–93.
16.
LamarcheBTchernofAMoorjaniS. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. prospective results from the Québec cardiovascular study. Circulation. 1997;95(1):69–75.
17.
AustinMABreslowJLHennekensCHBuringJEWillettWCKraussRM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260(13):1917–1921.
18.
GardnerCDFortmannSPKraussRM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276(11):875–881.
19.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
20.
KraussRM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med. 1998;105(1A):58S–62S.
21.
HultheJBokemarkLWikstrandJFagerbergB.The metabolic syndrome, LDL particle size, and atherosclerosis: the atherosclerosis and insulin resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000;20(9):2140–2147.
22.
FriedlanderYKidronMCaslakeMLambTMcConnellMBar-OnH. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis. 2000;148(1):141–149.
23.
GrundySM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95(1):1–4.
24.
WattsGFBarrettPHJiJ. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003;52(3):803–811.
25.
BilzSWagnerSSchmitzMBedynekAKellerUDemantT. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res. 2004;45(1):174–185.
26.
Bach-NgohouKOuguerramKFrénaisR. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. J Pharmacol Exp Ther. 2005;315(1):363–369.
27.
SkalickyJMuzakovaVKandarRMelounMRousarTPalickaV. Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med. 2008;46(4):499–505.
28.
ZalbaGSan JoséGMorenoMU. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 2001;38(6):1395–1399.
29.
BrasierARRecinosAIIIEledrisiMS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22(8):1257–1266.
30.
KnoppRHParamsothyP. Oxidized LDL and abdominal obesity: a key to understanding the metabolic syndrome. Am J Clin Nutr. 2006;83(1):1–2.
31.
BlockGDietrichMNorkusEP. Factors associated with oxidative stress in human populations. Am J Epidemiol. 2002;156(3):274–285.
32.
DietrichMBlockGHudesM. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev. 2002;11(1):7–13.
33.
TrevisanMBrowneRRamM. Correlates of markers of oxidative status in the general population. Am J Epidemiol. 2001;154(4):348–356.
34.
WeinbrennerTSchröderHEscurriolV. Circulating oxidized LDL is associated with increased waist circumference independent of body mass index in men and women. Am J Clin Nutr. 2006;83(1):30–35.
35.
FröhlichMImhofABergG. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835–1839.
36.
Van GuilderGPHoetzerGLGreinerJJStaufferBLDesouzaCA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). 2006;14(12):2127–2131.
37.
DasUN. Obesity, metabolic syndrome X, and inflammation. Nutrition. 2002;18(5):430–432.
38.
UndasABrummel-ZiedinsKEMannKG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost. 2013;111(3):392–400.
39.
KrysiakROkopieńBHermanZ. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003;63(17):1821–1854.
40.
RoebuckKA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med. 1999;4(3):223–230.
41.
LaneN. A unifying view of ageing and disease: the double-agent theory. J Theor Biol. 2003;225(4):531–540.
42.
DavìGGuagnanoMTCiabattoniG. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288(16):2008–2014.
43.
WrightEJrScism-BaconJLGlassLC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2006;60(3):308–314.
44.
RajpathakSNKumbhaniDJCrandallJBarzilaiNAldermanMRidkerPM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–1929.
45.
BellDSDinicolantonioJJO'KeefeJH. Is statin-induced diabetes clinically relevant? a comprehensive review of the literature. Diabetes Obes Metab. 2014;16(8):689–694.
